This study aims to evaluate nerve excitability in participants with cisplatin-induced peripheral neuropathy (cis-PN) using threshold tracking nerve conduction studies (TTNCS). By assessing changes in nerve excitability parameters, the study seeks to enhance understanding of the pathophysiology of cis-PN and identify early markers of neurotoxicity in participants undergoing cisplatin-based chemotherapy.
Adults age ≥ 18 who will begin cisplatin-based chemotherapy either alone or in combination with other agents that are not known to cause neuropathy.
Participants must have adequate hematologic parameters to allow chemotherapy.
Pre-existing peripheral neuropathy;
Family history of a genetic/familial neuropathy;
Any contraindication for treatment with cisplatin as determined by their primary oncologist;
Chemotherapy regimen combining cisplatin with another known chemotherapy agent that may cause peripheral neuropathy;
Ka-Wai Ho
Lead sponsor
Beth Israel Deaconess Medical Center
Sponsor institution
Dana-Farber Cancer Institute
Collaborator